1. Abu-Rish EY, Dahabiyeh LA, Bustanji Y, Mohamed YS, Browning MJ. Effect of lamotrigine on in vivo and in vitro cytokine secretion in murine model of inflammation. J Neuroimmunol. 2018 Sep 15;322:36-45. doi: 10.1016/j.jneuroim.2018.06.008. Epub 2018 Jun 11. PMID: 29937116. [cited 2026 April 21]
2. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014 Aug;121(8):799-817. doi: 10.1007/s00702-014-1180-8. Epub 2014 Mar 1. PMID: 24578174; PMCID: PMC4133642. [cited 2026 April 21]
3. Cunningham MO, Jones RS “The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro” abstract, PubMed, 2000 Aug 23 [cited 2026 April 21]
4. Suleman N, Ozdemirli M, Weisman D. Lamotrigine-associated hemophagocytic lymphohistiocytosis. BMJ Case Rep. 2021 Jan 6;14(1):e238183. doi: 10.1136/bcr-2020-238183. PMID: 33408106; PMCID: PMC7789038. [cited 2026 April 21]
5. Ventegodt S, Andersen NJ, Neikrug S, Kandel I, Merrick J. Clinical holistic medicine: holistic treatment of mental disorders. ScientificWorldJournal. 2005 May 23;5:427-45. doi: 10.1100/tsw.2005.50. PMID: 15915297; PMCID: PMC5936582. [cited 2026 April 21]
6. Wang-Tilz Y, Tilz C, Wang B, Pauli E, Koebnick C, Stefan H. “Changes of seizures activity during rapid withdrawal of lamotrigine.” Eur J Neurol. 2005 Apr;12(4):280-8. doi: 10.1111/j.1468-1331.2004.01101.x. PMID: 15804245.[cited April 21]
7. Klepper J, Leiendecker B. GLUT1 deficiency syndrome–2007 update. Dev Med Child Neurol. 2007 Sep;49(9):707-16. doi: 10.1111/j.1469-8749.2007.00707.x. PMID: 17718830. [cited 2026 April 21]
8. Frey LC, Strom LA, Shrestha A, Spitz MC. End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. Epilepsy Behav. 2009 Aug;15(4):521-3. doi: 10.1016/j.yebeh.2009.05.008. Epub 2009 Jul 29. PMID: 19643671.[cited 2026 April 21]
9. Economou NT, Bonakis A, Ghika A, Ferini-Strambi L, Vassilopoulos D, Kyrozis A. Lamotrigine withdrawal may worsen RBD symptoms. Neurologist. 2011 Sep;17(5):279-81. doi: 10.1097/NRL.0b013e31822c3e5d. PMID: 21881472. [cited 2026 April 21]
10. Iranzo A, Molinuevo JL, Santamaría J, Serradell M, Martí MJ, Valldeoriola F, Tolosa E. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 2006 Jul;5(7):572-7. doi: 10.1016/S1474-4422(06)70476-8. PMID: 16781987.[cited 2026 April 21]
11. Gelisse P, Kissani N, Crespel A, Jafari H, Baldy-Moulinier M. Is there a lamotrigine withdrawal syndrome? Acta Neurol Scand. 2002 Mar;105(3):232-4. doi: 10.1034/j.1600-0404.2002.1c220.x. PMID: 11886370. [cited 2026 April 21]
12. Prescribers Digital Reference “Lamotrigine – Drug Summary” [published online 2021] [cited April 2026 21]
13. Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf. 2004;27(3):173-84. doi: 10.2165/00002018-200427030-00002. PMID: 14756579. [cited 2026 April 21]
14. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Spotlight on lamotrigine in bipolar disorder. CNS Drugs. 2004;18(1):63-7. doi: 10.2165/00023210-200418010-00007. PMID: 14731061.[cited 2026 April 21]
15. Frey LC, Strom LA, Shrestha A, Spitz MC. End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. Epilepsy Behav. 2009 Aug;15(4):521-3. doi: 10.1016/j.yebeh.2009.05.008. Epub 2009 Jul 29. PMID: 19643671. [cited 2026 April 21]
16. Cosci F, Chouinard G: Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom 2020;89:283-306. doi: 10.1159/000506868 [cited 2026 April 21]
17. Ketter TA, Malow BA, Flamini R, et al. Anticonvulsant withdrawal-emergent psychopathology. Neurology. 1994 Jan;44(1):55-61. DOI: 10.1212/wnl.44.1.55. PMID: 8290092. [cited 2026 April 21]
18. Baldessarini RJ, Tondo L, Viguera AC. Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord. 1999 Sep;1(1):17-24. doi: 10.1034/j.1399-5618.1999.10106.x. PMID: 11256650. [cited 2026 April 21]
19. Hesdorffer DC, Berg AT, Kanner AM. An update on antiepileptic drugs and suicide: are there definitive answers yet?. Epilepsy Curr. 2010;10(6):137-145. doi:10.1111/j.1535-7511.2010.01382.x [cited 2026 April 21]
20. Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007 Dec;164(12):1817-24; quiz 1923. doi: 10.1176/appi.ajp.2007.06101639. PMID: 18056236. [cited 2026 April 21]
21. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002 Aug;63(8):737-41. doi: 10.4088/jcp.v63n0813. PMID: 12197456. [cited 2026 April 21]
22. CAMH Information Letter, “Mood Stabilizing Medications.” [published online 2009/2012] [cited 2026 April 21]
23. Goodman A. Addiction: definition and implications. Br J Addict. 1990 Nov;85(11):1403-8. doi: 10.1111/j.1360-0443.1990.tb01620.x. PMID: 2285834.[cited 2026 April 21]
24. FDA label Lamictal (lamotrigine) tablets for oral use, chewable dispersable tablets for uoral use, orally disintegrating tablets, {online} approval 1994 [cited 2026 April 21]
25. Betchel NT, Fariba KA, Saadabadi A. Lamotrigine. [Updated 2022 Feb 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470442/ [cited April 21]
26. Khateb M, Bosak N, Herskovitz M. The Effect of Anti-seizure Medications on the Propagation of Epileptic Activity: A Review. Front Neurol. 2021 May 27;12:674182. doi: 10.3389/fneur.2021.674182. PMID: 34122318; PMCID: PMC8191738.[cited 2026 April 21]
27. Rissardo JP, Fornari Caprara AL. Lamotrigine-Associated Movement Disorder: A Literature Review. Neurol India. 2021 Nov-Dec;69(6):1524-1538. doi: 10.4103/0028-3886.333440. PMID: 34979637. [cited 2026 April 21]
28. De Bellis M, d’Orsi G, Rubino EM, Arigliano C, Carella M, Sciruicchio V, Liantonio A, De Luca A, Imbrici P. Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice. Front Pharmacol. 2025 Jul 10;16:1584566. doi: 10.3389/fphar.2025.1584566. PMID: 40709084; PMCID: PMC12287013. [cited 2026 April 21]